Unum Therapeutics Inc. (UMRX): Price and Financial Metrics


Unum Therapeutics Inc. (UMRX)

Today's Latest Price: $0.56 USD

0.03 (-5.52%)

Updated May 29 4:00pm

Add UMRX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

UMRX Stock Summary

  • Unum Therapeutics Inc's stock had its IPO on March 29, 2018, making it an older stock than just 5.64% of US equities in our set.
  • Revenue growth over the past 12 months for Unum Therapeutics Inc comes in at 150.56%, a number that bests 96.04% of the US stocks we're tracking.
  • The volatility of Unum Therapeutics Inc's share price is greater than that of 95.95% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Unum Therapeutics Inc are CLDX, PIRS, KALV, ETTX, and SYBX.
  • UMRX's SEC filings can be seen here. And to visit Unum Therapeutics Inc's official web site, go to www.unumrx.com.
UMRX Daily Price Range
UMRX 52-Week Price Range

UMRX Stock Price Chart More Charts


UMRX Price/Volume Stats

Current price $0.56 52-week high $3.65
Prev. close $0.59 52-week low $0.30
Day low $0.53 Volume 851,456
Day high $0.63 Avg. volume 428,274
50-day MA $0.43 Dividend yield N/A
200-day MA $0.94 Market Cap 17.49M

Unum Therapeutics Inc. (UMRX) Company Bio


Unum Therapeutics Inc., a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient’s immune system to cure cancer. Its lead product candidate is the ACTR087 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory non-Hodgkin lymphoma. The company’s product portfolio also includes ACTR707 used in combination with rituximab that is in Phase I clinical trials to treat adult patients with r/r B cell non-Hodgkin lymphoma; ACTR087 used in combination with SEA-BCMA, which is in Phase I clinical trials for treating patients with r/r multiple myeloma; and ACTR707 used in combination with trastuzumab, which is in late preclinical development phase for treating HER2+ solid tumor cancers. It has strategic collaboration with Seattle Genetics, Inc. to identify, research, develop, and commercialize antibody-coupled T cell receptor therapies. The company was founded in 2014 and is based in Cambridge, Massachusetts.


UMRX Latest News Stream


Event/TimeNews Detail
Loading, please wait...

UMRX Latest Social Stream


Loading social stream, please wait...

View Full UMRX Social Stream

Latest UMRX News From Around the Web

Below are the latest news stories about Unum Therapeutics Inc that investors may wish to consider to help them evaluate UMRX as an investment opportunity.

Is Unum Therapeutics Inc. (UMRX) A Good Stock To Buy?

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 821 13F filings submitted by hedge funds and prominent investors. These filings show these funds' portfolio positions as of March 31st, 2020. […]

Yahoo | May 28, 2020

Unum Therapeutics Inc (UMRX) Reports Q1 Loss, Tops Revenue Estimates

Unum Therapeutics Inc (UMRX) delivered earnings and revenue surprises of 39.39% and 134.37%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | May 11, 2020

Unum Therapeutics Reports First Quarter Financial Results and Provides Corporate Updates

Unum Therapeutics Inc. (UMRX), a biopharmaceutical company focused on developing curative cell therapies for solid tumors, today announced financial results for the first quarter ended March 31, 2020, and provided corporate updates. Announced plans to prioritize resources towards advancing its preclinical program, BOXR1030, for the treatment of solid tumor cancers: On March 2nd, Unum announced a corporate restructuring plan to prioritize resources towards advancing its preclinical program, BOXR1030, for the treatment of solid tumor cancers. Unum’s BOXR1030 expresses a glypican-3 (GPC3) targeted CAR and incorporates the novel transgene glutamic-oxaloacetic transaminase 2 (GOT2) to improve T cell function in the solid tumor microenvironment by enhancing T cell metabolism.

Yahoo | May 11, 2020

What's in Store for Unum Therapeutics' (UMRX) Q1 Earnings?

During Unum Therapeutics' (UMRX) upcoming Q1 earnings call, investor focus will be on the company's progress pertaining to its preclinical program, BOXR1030, for treating solid tumor cancers.

Zacks Investment Research | April 28, 2020

Unum Therapeutics Inc. (UMRX) Q4 Earnings and Revenues Beat Estimates

Unum Therapeutics Inc. (UMRX) delivered earnings and revenue surprises of 120.00% and 271.07%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | March 26, 2020

Read More 'UMRX' Stories Here

UMRX Price Returns

1-mo 40.00%
3-mo -16.42%
6-mo -23.86%
1-year -83.63%
3-year N/A
5-year N/A
YTD -22.24%
2019 -83.63%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Continue Researching UMRX

Want to see what other sources are saying about Unum Therapeutics Inc's financials and stock price? Try the links below:

Unum Therapeutics Inc (UMRX) Stock Price | Nasdaq
Unum Therapeutics Inc (UMRX) Stock Quote, History and News - Yahoo Finance
Unum Therapeutics Inc (UMRX) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.762 seconds.